<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this study, we examined a large number of patients to clarify the distribution and frequency of a recently described FLT3 tandem duplication among <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e>, including 112 <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 55 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), 37 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 20 <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 30 non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), 14 adult T cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 15 <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) and 38 <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) </plain></SENT>
<SENT sid="1" pm="."><plain>We also evaluated 71 cell lines derived from 11 AML, 31 ALL, two hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, three <z:hpo ids='HP_0011009'>acute</z:hpo> unclassified <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 10 <z:mp ids='MP_0005481'>CML</z:mp>, 12 NHL including six Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and two MM </plain></SENT>
<SENT sid="2" pm="."><plain>Using genomic PCR of exon 11 coding for the juxtamembrane (JM) domain and first amino acids of the 5'-tyrosine kinase (TK) domain, this length mutation was found only in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (22/112, 20%) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (1/37) </plain></SENT>
<SENT sid="3" pm="."><plain>According to the FAB subclassification, they were 5/18 (28%) of M1, 4/29 (14%) of M2, 3/17 (18%) of M3, 6/24 (25%) of M4, 4/20 (20%) of M5 and 1/9 of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blast in transformation </plain></SENT>
<SENT sid="4" pm="."><plain>In the various cell lines examined, this abnormality was determined in only one derived from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and never found in other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The sequence analysis of the abnormal PCR products revealed that 23 of 24 showed internal tandem duplication with or without insertion of <z:chebi fb="9" ids="36976">nucleotides</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>In one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, insertion and deletion without duplication was determined </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 24 lengthened sequences were in-frame </plain></SENT>
<SENT sid="8" pm="."><plain>Duplication takes place in the sequence coding for the JM domain and leaves the TK domain intact </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, we emphasize that the length mutation of FLT3 at JM/TK-I domains were restricted to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Since <z:hpo ids='HP_0000001'>all</z:hpo> these mutations resulted in in-frame, this abnormality might function for the proliferation of leukemic cells </plain></SENT>
</text></document>